Cellebrite DI Ltd. $CLBT Holdings Boosted by Militia Capital Partners LP

Militia Capital Partners LP grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 200.0% in the 3rd quarter, Holdings Channel reports. The firm owned 90,000 shares of the company’s stock after acquiring an additional 60,000 shares during the quarter. Militia Capital Partners LP’s holdings in Cellebrite DI were worth $1,668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Financial Management Professionals Inc. acquired a new position in Cellebrite DI during the 3rd quarter valued at approximately $28,000. CWM LLC lifted its stake in Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in shares of Cellebrite DI during the third quarter valued at $38,000. PNC Financial Services Group Inc. boosted its holdings in shares of Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the period. Finally, Pacer Advisors Inc. grew its position in shares of Cellebrite DI by 523.4% during the third quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock worth $51,000 after acquiring an additional 2,303 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Trading Down 0.3%

Shares of CLBT opened at $14.40 on Tuesday. The business’s 50-day moving average price is $15.19 and its 200 day moving average price is $16.89. The stock has a market capitalization of $3.59 billion, a P/E ratio of 46.45, a P/E/G ratio of 2.21 and a beta of 1.30. Cellebrite DI Ltd. has a 1-year low of $11.76 and a 1-year high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, meeting analysts’ consensus estimates of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company had revenue of $128.82 million during the quarter, compared to analyst estimates of $126.07 million. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 28.8% on a year-over-year basis. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

CLBT has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, Needham & Company LLC dropped their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.